Why use adjuncts?
- LA is the primary component of neuraxial mixtures, but its adverse effects are dose dependent:
- Hypotension
- Motor block (and an associated ↑ risk of instrumental delivery)
- LA systemic toxicity
- Simply reducing the LA dose risks inadequate anaesthesia and breakthrough pain
- Adjuncts aim to allow a lower LA dose whilst maintaining (or improving) block quality, speed of onset and duration
The ideal neuraxial adjunct
| Pharmaceutical | Clinical |
| Preservative-free solution | Reduces effective dose of LA |
| Proven mechanism of action | Effective for both labour analgesia and caesarean section |
| Compatible with LA and other adjuncts | Prolongs analgesia without prolonging motor block |
| Predictable pharmacokinetics | Analgesia without excessive sedation |
| Effective via epidural and intrathecal routes | Minimal systemic adverse effects; not neurotoxic |
Licensing and neurotoxicity
- Many commonly used adjuncts are not licensed for neuraxial use i.e. their use is off-label
- Neurotoxicity may be direct, or indirect through ischaemia secondary to vasoconstriction
- Any drug given neuraxially must be preservative-free, as many preservatives are themselves neurotoxic
- Conversely, by reducing the LA dose, adjuncts may reduce the risk of LA-induced neurotoxicity